Issue Date: April 29, 2013
DSM Readies Aussie Biologics Facility
DSM plans a June start-up for its cGMP biologic drugs facility in Brisbane, Australia. Built with cooperation from local and national government agencies, the 500-kg-per-year facility will be Australia’s first custom mammalian-cell-based biopharmaceutical plant. Separately, DSM has signed an agreement to manufacture a therapeutic antibody for Cambridge, Mass.-based DecImmune Therapeutics. Initial development will take place in DSM’s plant in Groningen, the Netherlands; manufacturing of clinical trial material would occur at . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society